Most Volatile NYSE and NASDAQ Traded Stocks (THQI, VRNG, CDE, VVUS)

Los Angelas, CA -- (SBWIRE) -- 11/07/2012 -- Shares of THQ Inc. (Nasdaq:THQI) are trading at $1.50 and is -64.40% from its 50-day Moving Average price of $4.2133 and -73.39% from its 200-day Moving Average price of $5.6377. The average trading volume is 70249 shares and its market capitalization is $10.3M. THQ Inc. (THQI), the money-losing video-game company, fell the most in 21 years after posting a second- quarter loss and announcing it hired Centerview Partners LLC to evaluate its options and raise cash.THQ tumbled 50 percent to $1.50 at the close in New York, marking the biggest drop since November 1991. The shares have fallen 96 percent in the past two years, cutting the market value to less than $11 million. Centerview, an investment bank based in New York, will help THQ improve its cash reserves, preserve its ability to develop games and refinance $100 million of convertible debt, according to a statement yesterday. The 5 percent senior notes are due in August 2014.

How Should Investors React to THQI Now? Find Out Here

Vringo, Inc. Comm (AMEX:VRNG) is -0.38 - -9.62% from the previous close of $3.95. It traded between $3.00 - 4.42 with total traded volume of 37105232 shares. Keep a close eye on VRNG, as the stock has been showing unusual moves over the past weeks. At Current market price, VRNG has recovered +425.00% from its 52-week Low of 0.68 and has Pulled back -37.70% from its 52-week high of 5.73. Vringo (AMEX:VRNG) shares closed more than 9 percent in the red, but gained 2 percent in late trading. The technology firm was awarded $16 million in damages and a royalty on Google (NASDAQ:GOOG) search ad revenue through 2016 after winning its patent case against the search company on Tuesday. Vringo was originally seeking nearly $500 million, but U.S. District Judge Raymond A. Jackson limited damages to just the past year.

Get The Full Research Report On VRNG For Free: CLICK HERE

Coeur d'Alene Min (NYSE:CDE) reported EPS of 0.77. For the Current Fiscal year, the company is expected to report EPS of 1.39. For the Next Quarter and Next Year, the company is expected to report EPS of 0.73 and 3.47 respectively. At Current Market Price, CDE is in distance of -17.43% from its 50-day Moving Average price of $29.1871 and +11.95% from its 200-day Moving Average price of $21.5267. Shares of gold and silver miner Coeur d'Alene (NYSE:CDE) fell 23% today after reporting a surprising third-quarter loss. Third-quarter revenue fell 33% to $230.6 million, which was well below the $247.5 million analysts expected. But the big shocker was the $15.8 million, or $0.18 per share, loss the company reported. On an adjusted basis the company said it made a $0.29 per share profit versus the $0.39 expectation, but production problems and write-offs pushed the GAAP results lower. Third-quarter revenue fell 33% to $230.6 million, which was well below the $247.5 million analysts expected. But the big shocker was the $15.8 million, or $0.18 per share, loss the company reported. On an adjusted basis the company said it made a $0.29 per share profit versus the $0.39 expectation, but production problems and write-offs pushed the GAAP results lower.

Is CDE A Solid Investment At These Levels: Find Out Here

VIVUS, Inc. (NasdaqNM:VVUS) reported EPS of -0.688. For the Current Fiscal year, the company is expected to report EPS of -0.94. For the Next Quarter and Next Year, the company is expected to report EPS of -0.18 and 0.20 respectively. At Current Market Price, VVUS is in distance of -39.96% from its 50-day Moving Average price of $19.6856 and -48.53% from its 200-day Moving Average price of $22.9638. Shares of Vivus (NASDAQ:VVUS) lost more than 20 percent on the day after a disappointing third quarter report earlier on Tuesday. Even though revenue improved bottom line results missed estimates because of higher Qsymia-related costs. Moreover, the firm indicated in its conference call that the lack of insurer coverage is a “big concern,” and is impacting sales of the weight-loss drug.

Need Top Analysist Review On VVUS For Free: JUST CHECK HERE

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com